Researchers gain new insights into how the isotope astatine-211 interacts with resins commonly used to purify the isotope for therapeutic use Targeted Alpha Therapy (TAT) is one of the most powerful ...
Atley Solutions and Perceptive Discovery today announced the sale of two Atley C100 modules to Perceptive Discovery, marking the first step in a strategic collaboration aimed at establishing robust ...
Hosted on MSN
Targeted alpha therapy using astatine shows promise in thyroid cancer resistant to conventional treatment
A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting treatment. In a first-in-human study, ...
Hosted on MSN
Curadh MTR and Alpha Fusion to Spotlight Breakthrough Cancer Therapy at Radiopharmaceutical Summit
CHESTER SPRINGS, PA — Curadh MTR Inc. and Alpha Fusion, Inc. are set to showcase advances in cancer treatment using Astatine-211 (At-211) radiopharmaceuticals at the upcoming 4th Targeted ...
Naya Therapeutics Inc. is expanding its hepatocellular carcinoma pipeline with the addition of NY-700, a first-in-class GPC3-targeted Astatine-211 (211At) α radioimmunotherapy aiming to address ...
Astatine‑211 is increasingly recognized as the alpha emitter of choice for targeted radiotherapeutics. Its pure alpha emission results in high‑energy, short‑range cytotoxicity that selectively ...
Reston, VA (December 4, 2025)--A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting treatment. In a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results